Stage 3A: Potential Benefits of Adjuvant Treatment
It is important to know that adjuvant treatment may not be recommended for all patients with Stage 3A melanoma. Patients with a sentinel node metastasis of 1 mm or less have experienced little benefit from the treatment, and were not included in the original clinical trials. Your medical team should be able to help you with any questions you have about this.
Without Adjuvant Treatment
Figure A: Stage 3A Melanoma: Recurrence free at 5 years without treatment
Figure A explanatory : The diagram above shows data for individuals after receiving a Stage 3A melanoma diagnosis. It is based on a study using a global international melanoma database from ten countries (Eighth Edition International Melanoma Database)1.
For 100 people diagnosed with Stage 3A melanoma who are treated with surgery alone (and do not have adjuvant therapy), we would expect 93 people to have had no further recurrence of their melanoma five years after surgery. This is 93% of individuals — shown in yellow.
After the same period (within five years of their surgery), seven people in the group will have needed more treatment for their melanoma. The melanoma will therefore have recurred (returned) in 7% of individuals — shown in purple.
At ten years after surgery, 88% of people are recurrence free. The melanoma has returned in 12% of people.